OpGen Announces Date of Fourth Quarter and Fiscal Year 2018 Financial Results Conference Call
February 20 2019 - 9:00AM
OpGen, Inc. (NASDAQ: OPGN) announced today that
the Company will report its fourth quarter and fiscal year 2018
financial results after the close of the U.S. financial markets on
Tuesday, February 26, 2019. OpGen’s management team will host a
live conference call and audio webcast at 4:30 p.m. Eastern time to
discuss the Company’s financial results and business progress.
Dial-in InformationU.S. Dial-In Number: (888)
883-4599
International Dial-In Number: (484)
653-6821
Conference ID: 7268038
Replay Dial-in InformationU.S. Dial-In Number:
(855) 859-2056 International Dial-In Number: (404)
537-3406Conference ID: 7268038
Following the conclusion of the conference call, a replay will
be available through March 4, 2019. The live, listen-only webcast
of the conference call may also be accessed by visiting the
investors section of the Company’s website at www.ir.opgen.com. A
replay of the webcast will be available after the conclusion of the
call and will be archived on the Company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of
informatics and genomic analysis to provide complete solutions for
patient, hospital, and network-wide infection treatment and
prevention. The Acuitas Lighthouse® Software (RUO) is the first
cloud-based software to predict antibiotic resistance, track
antimicrobial resistance, and determine bacterial strain
relatedness in healthcare settings using bacterial genetic
data. The Acuitas® AMR Gene Panel (RUO) is the most
comprehensive, rapid PCR test for detecting five pathogens and 47
resistance genes which cover nine antibiotic classes. OpGen’s
solutions will provide the power to prescribe empiric therapy with
precision. For more information, please visit
www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are
registered trademarks of OpGen, Inc.
The Acuitas AMR Gene Panel u5.47 (RUO) and the
Acuitas Lighthouse Software (RUO) are intended for Research Use
Only and are not for use in diagnostic procedures. The Acuitas
Lighthouse Software is not distributed commercially for antibiotic
resistance prediction and is not for use in diagnostic
procedures.
OpGen Contact: Michael Farmer Vice President,
Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Investor Contacts: LHA Investor Relations Kim
Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com or Bruce Voss
(310) 691-7100 bvoss@lhai.com
Media ContactMatt BretziusFischTank Marketing
and PRmatt@fischtankpr.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024